Case Report


Capecitabine can do a wonder in metastatic triple negative breast cancer

,  

1 Department of Radiation Oncology, Paras HMRI Hospital, Patna, India

Address correspondence to:

Satyendra Narayan Sinha

Senior Resident, Department of Radiation Oncology, Paras HMRI Hospital, Patna,

India

Message to Corresponding Author


Article ID: 101071Z01SK2019

doi: 10.5348/101071Z01SK2019CR

Access full text article on other devices

Access PDF of article on other devices

How to cite this article

Keshri SK, Sinha SN. Capecitabine can do a wonder in metastatic triple negative breast cancer. Int J Case Rep Images 2019;10:101071Z01SK2019.

ABSTRACT


Introduction: Breast cancer is one of the most commonly diagnosed cancer in India and the leading cause of cancer death. Triple-negative breast cancer accounts for 15–20% of all breast cancers. Prognosis of triple negative breast cancer is very poor, and many women relapse quickly. There is very limited option and no standard recommended therapy available for previously treated patients with metastatic triple negative breast cancer (TNBC).

Case Report: A 50-year-old (age in 2019) female was diagnosed as a carcinoma left breast (stage pT2N1M0) triple negative in year 2008. After a diseasefree interval of eight years, in April 2017, she developed sternal and vertebral metastasis. She had received local palliative radiation to sternum along with zoledronic acid, and further, she continued zoledronic acid four weekly and started on oral capecitabine which she continued for 18 cycles. More than 11 years have been passed since initial diagnosis and at present she is perfectly alright without any disease and leading a normal life with ECOG 0.

Conclusion: In metastatic TNBC patients, single agent oral capecitabine can be a cost-effective and valid option which can do a wonder. We suggest a large clinical trial to validate this option in metastatic TNBC.

Keywords: Capecitabine, Capecitabine in mTNBC, Metastatic triple negative breast cancer

SUPPORTING INFORMATION


Author Contributions

Shekhar Kumar Keshri - Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published

Satyendra Narayan Sinha - Acquisition of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor of Submission

The corresponding author is the guarantor of submission.

Source of Support

None

Consent Statement

Written informed consent was obtained from the patient for publication of this article.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2019 Shekhar Kumar Keshri et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.